Floatz logo

Dpx-Survivac

Adult Refractory Diffuse Large B-Cell Lymphoma

ImmunoVaccine Technologies, Inc. (IMV Inc.)vaccinePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

107 Active assets in the Adult Refractory Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Selinexor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3BB
DEXAMETHASONE
City of Hope Medical Center
Phase 2/3BB
Axicabtagene Ciloleucel
Zhujiang Hospital
Phase 3BB
ETOPOSIDE
University of California, Davis
Phase 3BB
Ifosfamide
University of California, Davis
Phase 3BB

View all 50 →

Same molecule, other indications

Dpx-Survivac is also rated in:

ovarian carcinomaDormant
B
Indicative ·
59 / 100
View asset →
peritoneum cancerDormant
B
Indicative ·
57 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →